Alcoholic Hepatitis

Illustration of an enlarged, inflamed liver
Alcoholic hepatitis is a sudden, severe inflammatory liver disease in people with sustained heavy alcohol use.
Infographic: heavy alcohol use, liver inflammation, severity scoring and steroid response
The page describes heavy alcohol use, liver inflammation, the Maddrey and MELD severity scores, and the Lille score that tracks the response to steroids.
Histology view of liver tissue with ballooned cells and fat droplets
Liver biopsy in alcoholic hepatitis shows swollen liver cells, fat droplets and inflammation.

Alcoholic hepatitis is a severe, life-threatening inflammatory liver disease that develops suddenly in people with sustained heavy alcohol use — usually after decades of daily drinking exceeding 80–100 grams of alcohol per day. The paradox of alcoholic hepatitis is its timing: it can strike without warning in someone who has been drinking heavily for years without apparent liver trouble, and it can also develop even after a person reduces or stops drinking. Severe alcoholic hepatitis carries a 30-day mortality of 25–35% and a 90-day mortality up to 50% without treatment, making it one of the most immediately dangerous liver conditions in clinical medicine.

  1. Overview
  2. Epidemiology and Risk Factors
  3. Pathophysiology
  4. Clinical Presentation and Diagnosis
  5. Severity Scoring: Maddrey DF and MELD
  6. Liver Biopsy and Histology
  7. Treatment
  8. The Lille Score: Monitoring Steroid Response
  9. Key Research Papers
  10. Connections

🍺 Interactive Visualization What Alcohol Actually Does Inside Your Liver Ethanol becomes acetaldehyde becomes acetate — and the reduced nicotinamide adenine dinucleotide (NADH) that piles up shuts down fat burning, stalls your blood sugar and drives uric acid up. Nothing speeds it up. Launch →

Overview

Alcoholic hepatitis (AH) sits at the severe end of the alcohol-associated liver disease (ALD) spectrum, which ranges from alcoholic fatty liver (steatosis) through alcoholic hepatitis to alcoholic cirrhosis. The term "alcoholic hepatitis" specifically refers to the acute-on-chronic inflammatory syndrome — not to mildly elevated liver enzymes in a drinker. The key features are:

AH can develop in:

Back to Table of Contents

Epidemiology and Risk Factors

AH accounts for approximately 50,000–70,000 hospitalizations annually in the United States. In-hospital mortality from severe AH is 25–40%; 90-day mortality approaches 30–50% in MELD ≥21 cases.

Risk factors for developing AH from chronic alcohol use:

Back to Table of Contents

Pathophysiology

The central injury in AH flows from acetaldehyde toxicity and oxidative stress:

Step 1 — Alcohol metabolism and acetaldehyde: Hepatocytes metabolize >90% of ingested alcohol. Ethanol is oxidized by ADH (alcohol dehydrogenase) to acetaldehyde, and then by ALDH2 (aldehyde dehydrogenase) to acetate. Acetaldehyde is highly reactive — it forms protein adducts (Mallory-Denk bodies) and mitochondrial adducts that impair oxidative phosphorylation.

Step 2 — NADH-to-NAD+ imbalance: Alcohol oxidation by ADH shifts the hepatic redox state dramatically toward reduced nicotinamide adenine dinucleotide (NADH), raising the ratio of NADH to its oxidized form, nicotinamide adenine dinucleotide (NAD+). This inhibits gluconeogenesis (causing hypoglycemia) and fatty acid beta-oxidation (causing fatty acid accumulation/steatosis). Excess NADH also drives lactic acidosis.

Step 3 — Cytochrome P450 2E1 (CYP2E1) induction: Chronic alcohol use induces cytochrome P450 2E1, an alternative oxidative pathway that generates reactive oxygen species (ROS) — superoxide, hydrogen peroxide, hydroxyl radicals. Reactive oxygen species attack hepatocyte membranes, mitochondria, and nuclear DNA.

Step 4 — Gut barrier disruption and endotoxin translocation: Alcohol disrupts tight junctions between intestinal epithelial cells, increasing gut permeability. Bacterial endotoxin (lipopolysaccharide, LPS) floods the portal circulation, activating hepatic Kupffer cells via TLR4 signaling. Kupffer cells release massive amounts of tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and IL-8, creating the inflammatory cytokine storm that drives hepatocyte necrosis.

Step 5 — Neutrophilic infiltration: Unlike most forms of hepatitis where lymphocytes predominate, AH is characterized by neutrophilic infiltration of the liver parenchyma — a histological hallmark that reflects the acute-phase cytokine response.

Step 6 — Stellate cell activation and acute fibrosis: Simultaneously, activated hepatic stellate cells produce collagen at an accelerated rate, sometimes causing fibrosis to progress weeks to months in AH that would have taken years in metabolic dysfunction-associated steatotic liver disease (MASLD).

Back to Table of Contents

Clinical Presentation and Diagnosis

AH is diagnosed by a combination of clinical presentation, laboratory findings, and exclusion of competing diagnoses. Liver biopsy is confirmatory but not always required.

Clinical features:

Laboratory findings:

Key differential diagnoses:

Back to Table of Contents

Severity Scoring: Maddrey DF and MELD

Severity stratification guides treatment decisions in AH. Two scores are widely used:

Maddrey Discriminant Function (DF):

Formula: DF = 4.6 × (PTpatient − PTcontrol) + serum bilirubin (mg/dL)

MELD Score (Model for End-Stage Liver Disease):

Formula: 9.57 × log(creatinine) + 3.78 × log(bilirubin) + 11.2 × log(international normalized ratio) + 6.43

ABIC Score (Age-Bilirubin-INR-Creatinine):

Back to Table of Contents

Liver Biopsy and Histology

Liver biopsy in AH is confirmatory when diagnosis is clinically uncertain. Histological findings:

Characteristic features (Desmet-Scheuer criteria):

Fibrosis patterns:

Biopsy can be performed transjugularly in coagulopathic patients (international normalized ratio >1.5 is the usual threshold for percutaneous biopsy; transjugular route avoids bleeding risk).

Back to Table of Contents

Treatment

Treatment of severe AH (Maddrey DF ≥32 or MELD ≥21) has four pillars:

1. Absolute abstinence

Abstinence is the single most important intervention across all AH severity levels. Even in severe AH where corticosteroids are used, abstinence is the cornerstone — it reduces 6-month and 1-year mortality, prevents relapse, and may allow reversal of fibrosis. Addiction medicine consultation and social support during hospitalization improve long-term abstinence rates.

2. Nutritional support

Protein-calorie malnutrition is present in nearly all patients with AH and independently worsens outcomes:

3. Corticosteroids (prednisolone) for severe AH

The STOPAH trial (Thursz et al., NEJM 2015) is the landmark trial:

A 2018 meta-analysis of individual patient data from 11 randomized trials (2,111 patients) found that corticosteroids lowered the risk of death within 28 days compared with placebo or control (hazard ratio 0.64, 95% confidence interval 0.48–0.86), but there was no significant difference in 6-month mortality; adding pentoxifylline to corticosteroids made no difference to 28-day mortality. The 2024 American College of Gastroenterology guideline describes corticosteroids as the only drug treatment with proven efficacy in severe alcohol-associated hepatitis, giving a 1-month survival benefit in 50%–60% of patients.

Prednisolone is initiated at 40 mg/day orally × 28 days, followed by taper over 2 weeks. Response is assessed at day 7 using the Lille score (see below).

4. Liver transplantation for non-responders

Early liver transplantation for carefully selected severe AH non-responders was tested in a 2011 cohort from seven centres (Mathurin and colleagues): 26 patients were placed on the transplant list within a median of 13 days after failing to respond to medical therapy, and fewer than 2% of patients admitted with severe alcoholic hepatitis were selected:

Back to Table of Contents

The Lille Score: Monitoring Steroid Response

The Lille score, calculated on day 7 of prednisolone, predicts the likelihood of benefit from continuing corticosteroids.

How it is built: the Lille model (Louvet and colleagues, 2007) is a logistic-regression model that combines six measurements — age, kidney failure (renal insufficiency), albumin, prothrombin time, bilirubin, and the change in bilirubin by day 7 — into a score between 0 and 1. It was developed in 320 patients with severe AH treated with corticosteroids and checked in a further 118. It predicted death at 6 months better than the Child-Pugh and Maddrey scores, and in the validation group better than the MELD and Glasgow scores. Patients above the cutoff of 0.45 — about 40% of cases — had 25% 6-month survival, against 85% for the others, and this cutoff picked out about 75% of the deaths.

Interpretation:

The Lille score is now the standard of care in managing steroid therapy for AH and is incorporated into EASL, AASLD, and ACG guidelines. Continuing prednisolone in a Lille non-responder offers no survival benefit and increases infection (including aspergillosis) risk.

Back to Table of Contents

Key Research Papers

  1. — Thursz MR et al. "Prednisolone or Pentoxifylline for Alcoholic Hepatitis." New England Journal of Medicine 2015. — PubMed PMID: 25901427 (STOPAH trial)
  2. — Louvet A et al. "The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids." Hepatology 2007;45(6):1348-1354. (Lille score derivation) — PubMed PMID: 17518367
  3. — Mathurin P et al. "Early liver transplantation for severe alcoholic hepatitis." New England Journal of Medicine 2011. — PubMed PMID: 22070476
  4. — European Association for the Study of the Liver. "EASL Clinical Practice Guidelines: Management of alcohol-related liver disease." Journal of Hepatology 2018;69(1):154-181. — PubMed PMID: 29628280
  5. — Dunn W et al. "MELD accurately predicts mortality in patients with alcoholic hepatitis." Hepatology 2005. — PubMed PMID: 15660383
  6. — Dominguez M et al. "A new scoring system for prognostic stratification of patients with alcoholic hepatitis." American Journal of Gastroenterology 2008;103(11):2747-2756. (ABIC score) — PubMed PMID: 18721242
  7. — Singal AK et al. "ACG clinical guideline: alcoholic liver disease." American Journal of Gastroenterology 2018. — PubMed PMID: 29336434
  8. — Lucey MR et al. "Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases." Transplantation 1998;66(7):956-962. — PubMed PMID: 9798717
  9. — Maddrey WC et al. "Corticosteroid therapy of alcoholic hepatitis." Gastroenterology 1978. — PubMed PMID: 352788 (Maddrey DF original)
  10. — Crabb DW et al. "Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis." Gastroenterology 2016. — PubMed PMID: 26921783
  11. — Lazarus JV et al. "Advancing the global public health agenda for NAFLD." Nature Reviews Gastroenterology & Hepatology 2022. — Search PubMed
  12. — O'Shea RS et al. "Alcoholic liver disease." Hepatology 2010;51(1):307-328. (AASLD practice guidelines) — PubMed PMID: 20034030
  13. — Louvet A et al. "Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials." Gastroenterology 2018;155(2):458-468.e8. — PubMed PMID: 29738698
  14. — Jophlin LL et al. "ACG Clinical Guideline: Alcohol-Associated Liver Disease." American Journal of Gastroenterology 2024;119(1):30-54. — PubMed PMID: 38174913

Back to Table of Contents

Connections

Back to Table of Contents